Ovarian Cancer

Brian Slomovitz, MD, discusses key trials and surgical advances for patients with ovarian cancer.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

FDA grants fast track designation to a PARG inhibitor, ETX-19477, for the treatment of BRCA-mutated, platinum-resistant HGSOC.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

The FDA has granted breakthrough therapy designation to JSKN003 in HER2+ platinum-resistant ovarian cancer.

Alexander B. Olawaiye, MD, spotlights this phase 2 study evaluating bevacizumab plus relacorilant and nab-paclitaxel in platinum-resistant ovarian cancer.

Antonio González-Martín, MD, PhD, discusses data for TUB-040 in platinum-resistant ovarian cancer and how it stacks up against other ADCs.

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Read the most notable updates to the latest versions of the NCCN Clinical Practice Guidelines in Oncology across tumor types ahead of 2026.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

Maurie Markman, MD, discusses the evolving role of measurements in cancer care.

Initial activity and safety with the investigational ADC TUB-040 in ovarian cancer have renewed interest in NaPi2b as a target for ADC development.

The top 5 OncLive TV videos of the week cover insights in breast cancer and ovarian cancer.

Nicoletta Colombo, MD, PhD, discusses clinical implications for integrating immunotherapy into the treatment arsenal for platinum-resistant ovarian cancer.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in October 2025.

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

Mirvetuximab soravtansine has received a positive reimbursement recommendation in Canada under the Target Zero initiative for platinum-resistant ovarian cancer.

Experts reflect on pivotal data, emerging agents, and notable advancements in gynecologic cancer spotlighted during the 2025 ESMO Congress.

Raludotatug deruxtecan demonstrates antitumor activity and manageable safety in platinum-resistant ovarian cancer.

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

NAPISTAR1-01 showed enduring benefit with TUB-040 in patients with platinum-resistant high-grade serous ovarian cancer.

Pembrolizumab and paclitaxel with or without bevacizumab led to PFS and OS benefits vs placebo in place of pembrolizumab in recurrent, PD-L1–positive PROC.

Pembrolizumab plus chemotherapy with or without bevacizumab improved overall survival in platinum-resistant ovarian cancer.